Regan J. Lauer - 31 Jan 2024 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Chief Accounting Officer
Signature
/s/ Jason Liljestrom, as Attorney-in-Fact
Issuer symbol
IBRX
Transactions as of
31 Jan 2024
Net transactions value
-$45,259
Form type
4
Filing time
02 Feb 2024, 19:32:45 UTC
Previous filing
19 Dec 2023
Next filing
26 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Options Exercise $0 +32,872 +44% $0.000000 107,804 31 Jan 2024 Direct
transaction IBRX Common Stock Tax liability $45,259 -13,470 -12% $3.36 94,334 31 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Options Exercise $0 -32,872 -100% $0.000000* 0 31 Jan 2024 Common Stock 32,872 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2 Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award vested on January 31, 2024.